Procept Biorobotics Corp Stock Performance
| PRCT Stock | USD 57.05 1.30 2.23% |
Procept Biorobotics has a performance score of 2 on a scale of 0 to 100. The company holds a Beta of 0.56, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Procept Biorobotics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Procept Biorobotics is expected to be smaller as well. Procept Biorobotics Corp right now holds a risk of 2.71%. Please check Procept Biorobotics Corp value at risk, as well as the relationship between the skewness and day median price , to decide if Procept Biorobotics Corp will be following its historical price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Procept Biorobotics Corp are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable fundamental indicators, Procept Biorobotics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return (2.23) | Five Day Return (0.33) | Year To Date Return (31.40) | Ten Year Return 36.03 | All Time Return 36.03 |
1 | PROCEPT BioRobotics Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops | 04/24/2025 |
2 | Disposition of 13759 shares by Reza Zadno of Procept Biorobotics at 7.27 subject to Rule 16b-3 | 05/09/2025 |
3 | PROCEPT BioRobotics Corp Shares Up 6.15 percent on Jun 5 | 06/05/2025 |
4 | Disposition of 20000 shares by Hisham Shiblaq of Procept Biorobotics at 5.18 subject to Rule 16b-3 | 06/06/2025 |
5 | Acquisition by Prescott Thomas M of 2771 shares of Procept Biorobotics at 64.23 subject to Rule 16b-3 | 06/10/2025 |
6 | Disposition of 5717 shares by Desai Antal Rohit of Procept Biorobotics at 64.2727 subject to Rule 16b-3 | 06/11/2025 |
7 | Disposition of 5049 shares by Desai Antal Rohit of Procept Biorobotics at 62.3277 subject to Rule 16b-3 | 06/12/2025 |
8 | PROCEPT BioRobotics Co. Director Antal Rohit Desai Sells 25,000 Shares of Stock | 06/13/2025 |
9 | PROCEPT BioRobotics Corporation Receives Average Rating of Moderate Buy from Analysts | 06/27/2025 |
10 | Oppenheimer Initiates Coverage on PROCEPT BioRobotics PRCT Stock News | 07/07/2025 |
11 | Insiders At PROCEPT BioRobotics Sold US12m In Stock, Alluding To Potential Weakness | 07/09/2025 |
12 | Morgan Stanley Cuts PROCEPT BioRobotics Price Target to 68.00 | 07/15/2025 |
13 | Procept BioRobotics Gains from Medicares Favorable Decision PRCT Stock News | 07/16/2025 |
| Begin Period Cash Flow | 260.3 M | |
| Total Cashflows From Investing Activities | -4.4 M | |
| Free Cash Flow | -103.6 M |
Procept Biorobotics Relative Risk vs. Return Landscape
If you would invest 5,570 in Procept Biorobotics Corp on April 23, 2025 and sell it today you would earn a total of 135.00 from holding Procept Biorobotics Corp or generate 2.42% return on investment over 90 days. Procept Biorobotics Corp is currently generating 0.0753% in daily expected returns and assumes 2.7079% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Procept, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Procept Biorobotics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Procept Biorobotics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Procept Biorobotics Corp, and traders can use it to determine the average amount a Procept Biorobotics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0278
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | PRCT | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.71 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.08 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Procept Biorobotics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Procept Biorobotics by adding it to a well-diversified portfolio.
Procept Biorobotics Fundamentals Growth
Procept Stock prices reflect investors' perceptions of the future prospects and financial health of Procept Biorobotics, and Procept Biorobotics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Procept Stock performance.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | (0.40) % | ||||
| Current Valuation | 2.99 B | ||||
| Shares Outstanding | 55.33 M | ||||
| Price To Book | 8.30 X | ||||
| Price To Sales | 12.67 X | ||||
| Revenue | 224.5 M | ||||
| Gross Profit | 156.23 M | ||||
| EBITDA | (82 M) | ||||
| Net Income | (91.41 M) | ||||
| Cash And Equivalents | 269.81 M | ||||
| Cash Per Share | 6.05 X | ||||
| Total Debt | 80.25 M | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 16.01 X | ||||
| Book Value Per Share | 7.04 X | ||||
| Cash Flow From Operations | (99.21 M) | ||||
| Earnings Per Share | (1.69) X | ||||
| Market Capitalization | 3.16 B | ||||
| Total Asset | 534.02 M | ||||
| Retained Earnings | (545.99 M) | ||||
| Working Capital | 428.71 M | ||||
About Procept Biorobotics Performance
Assessing Procept Biorobotics' fundamental ratios provides investors with valuable insights into Procept Biorobotics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Procept Biorobotics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 234.57 | 292.80 | |
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.20) | (0.21) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.23) | (0.24) |
Things to note about Procept Biorobotics Corp performance evaluation
Checking the ongoing alerts about Procept Biorobotics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Procept Biorobotics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 224.5 M. Net Loss for the year was (91.41 M) with profit before overhead, payroll, taxes, and interest of 156.23 M. | |
| Procept Biorobotics Corp currently holds about 269.81 M in cash with (99.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.05. | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Procept BioRobotics Gains from Medicares Favorable Decision PRCT Stock News |
- Analyzing Procept Biorobotics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Procept Biorobotics' stock is overvalued or undervalued compared to its peers.
- Examining Procept Biorobotics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Procept Biorobotics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Procept Biorobotics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Procept Biorobotics' stock. These opinions can provide insight into Procept Biorobotics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Procept Stock Analysis
When running Procept Biorobotics' price analysis, check to measure Procept Biorobotics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procept Biorobotics is operating at the current time. Most of Procept Biorobotics' value examination focuses on studying past and present price action to predict the probability of Procept Biorobotics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procept Biorobotics' price. Additionally, you may evaluate how the addition of Procept Biorobotics to your portfolios can decrease your overall portfolio volatility.